Luciana Oliveira Cascaes Dourado et al. Cristian Paul Delgado Moreno Sarah Fagundes Grobe Luis Henrique Wolff Gowdak Luiz Antonio Machado Cesar
Introduction
Refractory angina (RA), an extremely debilitating condition, requires specialized medical treatment with often complex therapeutic adjustments in an attempt to improve symptoms and quality of life as much as possible.
Medical treatment usually comprises a combination of antianginal drugs (AAD). Among them, trimetazidine (T) and ranolazine (R) are an add-on therapy due to their efficacy and safety profile in the treatment of patients with RA. – However, in the recent “diamond approach”, depicting preferred combinations of different classes of AAD for the treatment of patients with angina, does not consider the concomitant use of T and R a useful strategy due to their related mechanism of action. Although no known interaction between both drugs has been described, there is no data on the efficacy and safety of the use of R in patients already on T. Therefore, we aimed to evaluate the effect of the concomitant use of R and T in patients with RA.
[…]